IP Library › Granted Patent US 10,640,543
Granted Patent B2
US 10,640,543 · App. 16/156,867 · Granted May 5, 2020

CD27 ligand (CD27L) single-chain fusion polypeptides

Inventors: Oliver Hill (Neckarsteinach, DE); Christian Gieffers (Dossenheim, DE); Meinolf Thiemann (Schriesheim, DE)
Assignee: APOGENIX AG
C07K14/525C07K14/70575C07K14/70578C07K16/00C12N15/62C12N15/79A61K38/00C07K2317/41C07K2317/52C07K2317/55C07K2319/00C07K2319/22C07K2319/30C07K2319/32C07K2319/35C07K2319/74
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,640,543
App. No.
16/156,867
Granted
May 5, 2020
Kind
B2
Abstract

The present invention refers to single-chain fusion proteins comprising three soluble TNF superfamily (TNFSF) cytokine domains and nucleic acid molecules encoding these fusion proteins. The fusion proteins are substantially non-aggregating and suitable for therapeutic, diagnostic and/or research applications.

Claims (17)

1. A single-chain fusion polypeptide comprising:

(i) a first soluble CD27 ligand (CD27L) cytokine domain,

(ii) a first peptide linker,

(iii) a second soluble CD27L cytokine domain,

(iv) a second peptide linker, and

(v) a third soluble CD27L cytokine domain,

wherein each of the soluble CD27L cytokine domains lacks a stalk region.

2. The polypeptide of claim 1 , wherein the first, the second, and the third soluble CD27L cytokine domains are, independently an N-terminally shortened domain of SEQ ID NO:7, and optionally consists of an amino acid mutation.

3. The polypeptide of claim 1 , wherein the first, the second, and the third soluble CD27L cytokine domains independently have the amino sequence of 51-193 or 56-193 of SEQ ID NO: 7.

4. The polypeptide of claim 1 , wherein the first and second peptide linkers are, independently, glycine/serine linkers.

5. The polypeptide of claim 4 , wherein the glycine/serine linkers comprise substituted asparagine residues.

6. The polypeptide of claim 1 , which additionally comprises an N-terminal signal peptide domain.

7. The polypeptide of claim 6 , wherein the N-terminal signal peptide domain comprises a protease cleavage site.

8. The polypeptide of claim 1 , which additionally comprises a further domain at the N-terminal and/or C-terminal end.

9. The polypeptide of claim 1 , which additionally comprises a further domain and a third peptide linker at the C-terminal end.

10. An isolated nucleic acid molecule encoding the fusion polypeptide of claim 1 .

11. An isolated host cell or a non-human organism transformed or transfected with the nucleic acid molecule of claim 10 .

Priority Claims (1)
EP 08013112 · Jul 21, 2008 · regional
Continuity (6)
Continuation 15643787 · Jul 7, 2017
Continuation 15172393 · Jun 3, 2016
Continuation 14320261 · Jun 30, 2014
Continuation 13902328 · May 24, 2013
Continuation 13055109
Related Publication 20190023759A1 · Jan 24, 2019
Cited By (1)
US 12,351,618